LLY

766.42

+0.37%↑

JNJ

154.5

+0.84%↑

ABBV

189.56

+0.91%↑

UNH

300.56

+0.77%↑

ABT

133.23

-0.1%↓

LLY

766.42

+0.37%↑

JNJ

154.5

+0.84%↑

ABBV

189.56

+0.91%↑

UNH

300.56

+0.77%↑

ABT

133.23

-0.1%↓

LLY

766.42

+0.37%↑

JNJ

154.5

+0.84%↑

ABBV

189.56

+0.91%↑

UNH

300.56

+0.77%↑

ABT

133.23

-0.1%↓

LLY

766.42

+0.37%↑

JNJ

154.5

+0.84%↑

ABBV

189.56

+0.91%↑

UNH

300.56

+0.77%↑

ABT

133.23

-0.1%↓

LLY

766.42

+0.37%↑

JNJ

154.5

+0.84%↑

ABBV

189.56

+0.91%↑

UNH

300.56

+0.77%↑

ABT

133.23

-0.1%↓

Search

Novo Nordisk A-S

Ouvert

SecteurSoins de santé

74.51 2.63

Résumé

Variation du prix de l'action

24h

Actuel

Min

72.3

Max

75.15

Chiffres clés

By Trading Economics

Revenu

804M

29B

Ventes

-7.6B

78B

P/E

Moyenne du Secteur

20.344

51.198

BPA

6.53

Rendement du dividende

2.22

Marge bénéficiaire

37.182

Employés

77,406

EBITDA

5.9B

46B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+27.46% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.22%

2.40%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

55B

321B

Ouverture précédente

71.88

Clôture précédente

74.51

Sentiment de l'Actualité

By Acuity

30%

70%

83 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Novo Nordisk A-S Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 mai 2025, 11:36 UTC

Actualités

Novo Nordisk CEO to Step Down Amid Market Challenges

12 mai 2025, 09:36 UTC

Principaux Mouvements du Marché

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 mai 2025, 11:29 UTC

Actualités
Résultats
Principaux Mouvements du Marché

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 mai 2025, 07:05 UTC

Résultats

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 mai 2025, 06:19 UTC

Résultats

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

3 juin 2025, 15:03 UTC

Acquisitions, Fusions, Rachats

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 mai 2025, 01:00 UTC

Actualités

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 mai 2025, 14:08 UTC

Résultats

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 mai 2025, 07:43 UTC

Market Talk

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 mai 2025, 18:35 UTC

Actualités

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 17:34 UTC

Actualités

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 mai 2025, 13:42 UTC

Actions en Tendance

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mai 2025, 13:27 UTC

Market Talk

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 mai 2025, 13:15 UTC

Actualités

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 mai 2025, 12:17 UTC

Résultats

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 mai 2025, 22:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 mai 2025, 15:13 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 mai 2025, 13:56 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mai 2025, 13:45 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 mai 2025, 11:25 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 mai 2025, 11:18 UTC

Résultats

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mai 2025, 09:55 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 mai 2025, 09:36 UTC

Résultats

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 mai 2025, 09:04 UTC

Résultats
Actions en Tendance

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 mai 2025, 08:10 UTC

Market Talk

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 mai 2025, 08:08 UTC

Market Talk

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 mai 2025, 07:11 UTC

Market Talk
Résultats

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Comparaison

Variation de prix

Novo Nordisk A-S prévision

Objectif de Prix

By TipRanks

27.46% hausse

Prévisions sur 12 Mois

Moyen 92.6 USD  27.46%

Haut 139.59 USD

Bas 61 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

3

Achat

4

Maintien

1

Vente

Score Technique

By Trading Central

62.63 / 69.23Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

83 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.